pH-dependent Binding Engineering Reveals an FcRn Affinity Threshold That Governs IgG Recycling

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Journal of Biological Chemistry

• Publication date

  2014-12-23

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1074/jbc.M114.603712PMID 25538249PMCID PMC4326836
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Structural Insights into Neonatal Fc Receptor-based Recycling Mechanisms

  2014cited by this paper
• A Novel Investigational Fc-Modified Humanized Monoclonal Antibody, Motavizumab-YTE, Has an Extended Half-Life in Healthy Adults

  2013cited by this paper
• Engineered Monoclonal Antibody with Novel Antigen-Sweeping Activity In Vivo

  2013cited by this paper
• Crystal structure of an HSA/FcRn complex reveals recycling by competitive mimicry of HSA ligands at a pH-dependent hydrophobic interface.

  2013cited by this paper
• FcRn Affinity-Pharmacokinetic Relationship of Five Human IgG4 Antibodies Engineered for Improved In Vitro FcRn Binding Properties in Cynomolgus Monkeys

  2012cited by this paper
• Monoclonal Antibodies with Identical Fc Sequences Can Bind to FcRn Differentially with Pharmacokinetic Consequences

  2011cited by this paper
• Antibodies with modified isoelectric points

  2011cited by this paper
• A therapeutic anti-VEGF antibody with increased potency independent of pharmacokinetic half-life.

  2010cited by this paper
• Importance of Neonatal FcR in Regulating the Serum Half-Life of Therapeutic Proteins Containing the Fc Domain of Human IgG1: A Comparative Study of the Affinity of Monoclonal Antibodies and Fc-Fusion Proteins to Human Neonatal FcR

  2010cited by this paper
• Pharmacokinetics of Humanized Monoclonal Anti-Tumor Necrosis Factor-α Antibody and Its Neonatal Fc Receptor Variants in Mice and Cynomolgus Monkeys

  2010cited by this paper
• Reduced elimination of IgG antibodies by engineering the variable region.

  2010cited by this paper
• Enhanced antibody half-life improves in vivo activity

  2010cited by this paper
• Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization

  2010cited by this paper
• Structural characterization of a human Fc fragment engineered for extended serum half-life.

  2009cited by this paper
• Engineering Human IgG1 Affinity to Human Neonatal Fc Receptor: Impact of Affinity Improvement on Pharmacokinetics in Primates

  2009cited by this paper
• Optimization of Fc-mediated effector functions of monoclonal antibodies.

  2009cited by this paper
• Molecular engineering and design of therapeutic antibodies.

  2008cited by this paper
• FcRn: the neonatal Fc receptor comes of age

  2007cited by this paper
• Monoclonal Antibody Clearance

  2007cited by this paper
• Humanized IgG1 Variants with Differential Binding Properties to the Neonatal Fc Receptor: Relationship to Pharmacokinetics in Mice and Primates

  2007cited by this paper
• Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract.

  2007cited by this paper
• Exploring "one-shot" kinetics and small molecule analysis using the ProteOn XPR36 array biosensor.

  2006cited by this paper
• Analysis of a family of antibodies with different half-lives in mice fails to find a correlation between affinity for FcRn and serum half-life.

  2006cited by this paper
• Properties of Human IgG1s Engineered for Enhanced Binding to the Neonatal Fc Receptor (FcRn)*

  2006influential reference
• Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels

  2005cited by this paper
• WebLogo: a sequence logo generator.

  2004cited by this paper
• Engineered Human IgG Antibodies with Longer Serum Half-lives in Primates*

  2004cited by this paper
• The Major Histocompatibility Complex–related Fc Receptor for IgG (FcRn) Binds Albumin and Prolongs Its Lifespan

  2003influential reference
• The MHC Class I-Like IgG Receptor Controls Perinatal IgG Transport, IgG Homeostasis, and Fate of IgG-Fc-Coupled Drugs1

  2003cited by this paper
• Increasing the Affinity of a Human IgG1 for the Neonatal Fc Receptor: Biological Consequences1

  2002cited by this paper
• High Resolution Mapping of the Binding Site on Human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcγR*

  2001cited by this paper
• Crystal structure at 2.8 A of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding.

  2001cited by this paper
• Multiple roles for the major histocompatibility complex class I- related receptor FcRn.

  2000cited by this paper
• Mapping the site on human IgG for binding of the MHC class I‐related receptor, FcRn

  1999cited by this paper
• Delineation of the amino acid residues involved in transcytosis and catabolism of mouse IgG1.

  1997cited by this paper
• Increased clearance of IgG in mice that lack β2‐microglobulin: possible protective role of FcRn

  1996cited by this paper
• Abnormally short serum half‐lives of IgG in β2‐microglobulin‐deficient mice

  1996cited by this paper
• Analysis of the pH dependence of the neonatal Fc receptor/immunoglobulin G interaction using antibody and receptor variants.

  1995cited by this paper
• Sequences of proteins of immunological interest

  1991cited by this paper
• Sequence logos: a new way to display consensus sequences.

  1990cited by this paper

• Impact of Neonatal Fc Receptor on Transferrin Receptor Antibody Fusion Protein Pharmacokinetics.

  2026cites this paper
• Half-life extension and immunogenicity in therapeutic proteins: mechanisms, trade-offs, and a decision framework.

  2026cites this paper
• Advancing protective effects of maternal antibodies in neonates through animal models.

  2025cites this paper
• Optimising Monoclonal Antibody Drug Development for Inflammatory Bowel Disease

  2025cites this paper
• Model‐Informed Optimal Dosing of Anti‐CD47 Antibody Using Target‐Mediated Drug Disposition Model

  2025cites this paper
• Translational minimal physiologically based pharmacokinetic model for transferrin receptor-mediated brain delivery of antibodies

  2025cites this paper
• Leveraging neonatal Fc receptor (FcRn) to enhance antibody transport across the blood brain barrier

  2025cites this paper
• Engineering FcRn binding kinetics dramatically extends antibody serum half-life and enhances therapeutic potential

  2025cites this paper
• Rapid depletion of “catch-and-release” anti-ASGR1 antibody in vivo

  2024cites this paper
• Efgartigimod versus intravenous immunoglobulin in the treatment of patients with impending myasthenic crisis

  2024cites this paper
• Cellular neonatal Fc receptor recycling efficiencies can differentiate target-independent clearance mechanisms of monoclonal antibodies.

  2024cites this paper
• Benralizumab: from tissue distribution to eosinophilic cytotoxicity up to potential immunoregulation

  2024influential citation
• Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows

  2024cites this paper
• Impact of structural modifications of IgG antibodies on effector functions

  2024cites this paper
• Fc engineered anti‐virus therapeutic human IgG1 expressed in plants with altered binding to the neonatal Fc receptor

  2024cites this paper
• Comprehensive approaches to preclinical evaluation of monoclonal antibodies and their next-generation derivatives.

  2024cites this paper
• In vivo mRNA expression of a multi-mechanistic mAb combination protects against Staphylococcus aureus infection

  2024cites this paper
• A bispecific antibody NXT007 exerts a hemostatic activity in hemophilia A monkeys enough to keep a non-hemophiliac state

  2023cites this paper
• Harnessing Fc/FcRn Affinity Data from Patents with Different Machine Learning Methods

  2023cites this paper
• Title: A bispecific antibody NXT007 exerts a hemostatic activity in hemophilia A monkeys enough to keep a non-hemophiliac state

  2023cites this paper
• Engineered Serum Markers for Noninvasive Monitoring of Gene Expression in the Brain

  2022influential citation
• Developability profiling of a panel of Fc engineered SARS-CoV-2 neutralizing antibodies

  2022cites this paper
• In Silico Analysis of Therapeutic Antibody Aggregation and the Influence of Glycosylation.

  2022cites this paper
• An Fc variant with two mutations confers prolonged serum half-life and enhanced effector functions on IgG antibodies

  2022cites this paper
• In vivo biodistribution and pharmacokinetics of sotrovimab, a SARS-CoV-2 monoclonal antibody, in healthy cynomolgus monkeys

  2022cites this paper
• Translational Approach for Predicting Human Pharmacokinetics of Engineered Therapeutic Monoclonal Antibodies with Increased FcRn-Binding Mutations

  2022cites this paper
• A Charge Variant of Bevacizumab Offers Enhanced FcRn-Dependent Pharmacokinetic Half-Life and Efficacy

  2022cites this paper
• Delivery of Orally Administered Digestible Antibodies Using Nanoparticles

  2021cites this paper
• Recent Achievements and Challenges in Prolonging the Serum Half-Lives of Therapeutic IgG Antibodies Through Fc Engineering

  2021cites this paper
• In Translation: FcRn across the Therapeutic Spectrum

  2021cites this paper
• Prevention of diabetes-associated fibrosis: Strategies in FcRn-targeted nanosystems for oral drug delivery.

  2021cites this paper
• In vivo pharmacokinetic enhancement of monomeric Fc and monovalent bispecific designs through structural guidance

  2021cites this paper
• Fc Receptor Variants and Disease: A Crucial Factor to Consider in the Antibody Therapeutics in Clinic

  2021cites this paper
• Functional in vitro assessment of modified antibodies: Impact of label on protein properties

  2021cites this paper
• Engineering Antibody-Based Therapeutics: Progress and Opportunities

  2021cites this paper
• V Region of IgG Controls the Molecular Properties of the Binding Site for Neonatal Fc Receptor

  2020cites this paper
• Pharmacokinetics of novel Fc-engineered monoclonal and multispecific antibodies in cynomolgus monkeys and humanized FcRn transgenic mouse models

  2020cites this paper
• Analysis of the intracellular traffic of IgG in the context of Down syndrome (trisomy 21)

  2020cites this paper
• Considerations for the Design of Antibody-Based Therapeutics.

  2020cites this paper
• Human IgG1 Fc pH-dependent optimization from a constant pH molecular dynamics simulation analysis

  2020cites this paper
• The biodistribution of therapeutic proteins: Mechanism, implications for pharmacokinetics, and methods of evaluation.

  2020cites this paper
• A Physiologically‐Based Pharmacokinetic Model for the Prediction of “Half‐Life Extension” and “Catch and Release” Monoclonal Antibody Pharmacokinetics

  2020influential citation
• Balancing the Affinity and Pharmacokinetics of Antibodies by Modulating the Size of Charge Patches on Complementarity-Determining Regions.

  2020cites this paper
• Antigen physiochemical properties allosterically effect the IgG Fc-region and Fc neonatal receptor affinity

  2020cites this paper
• Antibody Structure and Function: The Basis for Engineering Therapeutics

  2019cites this paper
• Contribution of DNA methylation to the expression of FCGRT in human liver and myocardium

  2019cites this paper
• An engineered human Fc domain that behaves like a pH-toggle switch for ultra-long circulation persistence

  2019cites this paper
• Quantitative Pharmacology Approach to Select Optimal Dose and Study the Important Factors in Determining Disposition of Therapeutic Monoclonal Antibody in Pediatric Subjects - Some Considerations

  2019cites this paper
• Heparin chromatography as an in vitro predictor for antibody clearance rate through pinocytosis

  2019cites this paper
• Antibody Fc engineering for enhanced neonatal Fc receptor binding and prolonged circulation half-life

  2019cites this paper
• Rapid bacteria detection at low concentrations using sequential immunomagnetic separation and paper-based isotachophoresis.

  2019cites this paper
• Radiolabeled IgG Antibodies - Impact of Various Labels on Neonatal Fc Receptor Binding.

  2019cites this paper
• A Physiologically‐Based Pharmacokinetic Model for the Prediction of Monoclonal Antibody Pharmacokinetics From In Vitro Data

  2019cites this paper
• Insights into the IgG heavy chain engineering patent landscape as applied to IgG4 antibody development

  2019cites this paper
• Histidine-mediated intramolecular electrostatic repulsion for controlling pH-dependent protein-protein interaction.

  2019cites this paper
• Targeting FcRn to Generate Antibody-Based Therapeutics.

  2018cites this paper
• A minimal physiologically based pharmacokinetic model to investigate FcRn-mediated monoclonal antibody salvage: Effects of Kon, Koff, endosome trafficking, and animal species

  2018cites this paper
• Subcutaneous delivery of monoclonal antibodies: How do we get there?

  2018cites this paper
• Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans

  2018cites this paper
• Extending human IgG half-life using structure-guided design

  2018cites this paper
• Establishing in vitro in vivo correlations to screen monoclonal antibodies for physicochemical properties related to favorable human pharmacokinetics

  2018cites this paper
• Effects of the FcRn developmental pharmacology on the pharmacokinetics of therapeutic monoclonal IgG antibody in pediatric subjects using minimal physiologically-based pharmacokinetic modelling

  2018cites this paper
• A human endothelial cell-based recycling assay for screening of FcRn targeted molecules

  2018cites this paper
• Toward a Combinatorial Approach for the Prediction of IgG Half-Life and Clearance

  2018cites this paper
• Minimal physiologically‐based pharmacokinetic model to investigate the effect of pH dependent FcRn affinity and the endothelial endocytosis on the pharmacokinetics of anti‐VEGF humanized IgG1 antibody in cynomolgus monkey

  2018cites this paper
• Antibody-mediated protection against Ebola virus

  2018cites this paper
• Pharmacokinetic and Pharmacodynamic Considerations in the Design of Therapeutic Antibodies

  2018influential citation
• Novel Constructs—Half-Life Extensions

  2018cites this paper
• Two-Pore Minimum Physiologically-based Pharmacokinetic Model to Describe the Disposition of Therapeutic Monoclonal IgG Antibody in Humans

  2018cites this paper
• Maximizing in vivo target clearance by design of pH-dependent target binding antibodies with altered affinity to FcRn

  2017cites this paper
• Rapid Purification of Human Bispecific Antibodies via Selective Modulation of Protein A Binding

  2017cites this paper
• Predicting pharmacokinetic profile of therapeutic antibodies after iv injection from only the data after sc injection in cynomolgus monkey

  2017cites this paper
• DMAb inoculation of synthetic cross reactive antibodies protects against lethal influenza A and B infections

  2017cites this paper
• Next generation antibody drugs: pursuit of the 'high-hanging fruit'

  2017cites this paper
• Enhancement of antibody functions through Fc multiplications

  2017cites this paper
• An "Fc-Silenced" IgG1 Format With Extended Half-Life Designed for Improved Stability.

  2017cites this paper
• Identification of human IgG1 variant with enhanced FcRn binding and without increased binding to rheumatoid factor autoantibody

  2017cites this paper
• Engineering a pH responsive pore forming protein

  2017cites this paper
• An antidote approach to reduce risk and broaden utility of antibody-based therapeutics

  2017cites this paper
• Changes in complementarity-determining regions significantly alter IgG binding to the neonatal Fc receptor (FcRn) and pharmacokinetics

  2017cites this paper
• Quantitative prediction of therapeutic antibody pharmacokinetics after intravenous and subcutaneous injection in human.

  2017cites this paper
• Mehanizem tvorbe por listeriolizina O iz Listeria monocytogenes in perforinu podobnega proteina 3 iz Plasmodium falciparum : [doktorska disertacija]

  2017cites this paper
• Protein Engineering: Methods and Applications

  2017cites this paper
• Immunoglobulines génétiquement transformées ayant une liaison à fcrn altérée

  2017cites this paper
• Mechanism-Based Competitive Binding Model to Investigate the Effect of Neonatal Fc Receptor Binding Affinity on the Pharmacokinetic of Humanized Anti-VEGF Monoclonal IgG1 Antibody in Cynomolgus Monkey

  2016cites this paper
• Enhanced FcRn-dependent transepithelial delivery of IgG by Fc-engineering and polymerization.

  2016cites this paper
• Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies

  2016cites this paper
• Single chain antibody fragments with pH dependent binding to FcRn enabled prolonged circulation of therapeutic peptide in vivo.

  2016cites this paper
• The Highly Evolvable Antibody Fc Domain.

  2016cites this paper
• A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life

  2015cites this paper
• The multiple facets of FcRn in immunity

  2015cites this paper
• Targeting FcRn for the modulation of antibody dynamics.

  2015cites this paper
• Conformational Destabilization of Immunoglobulin G Increases the Low pH Binding Affinity with the Neonatal Fc Receptor*

  2015influential citation